N
← Back to Search
Sponsored

Accelerate Your Clinical Trial Recruitment

Reach thousands of high-intent patients matching your specific inclusion criteria.

Start Campaign
RECRUITING Not applicable ClinicalTrials.gov

Supportive Psychoeducational Intervention for Patients With Brain Tumors (Acceptance and Commitment Therapy-based Supportive Intervention for Patients With Central Nervous System Tumors)

Sponsor: Massachusetts General Hospital • ClinicalTrials.gov ID: NCT06099743

Registry updated: 2026-10-07
Ad

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Check Eligibility →

Description

The goal of this study is to refine and test a psychosocial intervention called ASCENT (ACT-based Supportive intervention for patients with CENTral nervous system tumors). This intervention was developed to help patients after being diagnosed with a brain tumor. The main question this study aims to answer is whether this intervention is feasible (i.e., possible to carry out) and acceptable (i.e., considered helpful) to patients. Participants will be asked to take part in 6 coaching sessions and complete short surveys at four different time points. Some participants will be asked to share feedback via interviews.

Interventions

  • Psychosocial intervention (Behavioral)
    Intervention manual and six one-on-one coaching sessions.
  • Usual supportive care (Other)
    Referral to cancer center supportive care services (e.g., social work) as needed, upon request from the patient, caregiver, or clinician.

Eligibility criteria

Inclusion Criteria: * Age ≥ 18 * Massachusetts General Hospital Cancer Center Patient * Diagnosed with a malignant primary Central Nervous System (CNS) tumor * English speaking Exclusion Criteria: * Inability to provide informed consent as assessed by the study team (e.g., due to severe cognitive impairment/dementia) * Moderate to severe receptive aphasia (Quick Aphasia Battery sentence comprehension subscale \< 8) * Deemed by treating team to have less than 6 month life expectancy, including patients with current or imminent hospice enrollment * Current participant in the NeuroTransitions (23-574) or NeuroPathways (23-178) studies at Massachusetts General Hospital * Diagnosis of Primary CNS Lymphoma

Conditions

Malignant Brain Tumor Glioma Coping Skills Distress, Emotional

Locations

  • Massachusetts General Hospital Cancer Center — Boston, Massachusetts, United States
Sponsored

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record